QGEN

QIAGEND

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$39.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$35.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$29.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

Headline flow remains high because the stock is still digesting the April 27, 2026 preliminary results and FY2026 outlook cut, the May 6 full-results confirmation, and the May 7 QuantiFERON workflow announcement. The May 7 anchor price of $33.51 sits below the newly cited $38-$45 post-reset analyst targets, but the revision pattern is mostly target cuts with only selective rating support; missing broader estimate-revision evidence keeps this a cautious monitoring view rather than a strong post-earnings recovery call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-08-01catalystPost-earnings reset must stabilize after FY2026 cut [#6K-2026-04-27]Medium impact

QIAGEN's SEC-furnished preliminary Q1 2026 release confirmed net sales of $492 million, down 1% CER versus an outlook for at least 1% CER growth, adjusted diluted EPS of $0.54 in line with outlook, and a reduced FY2026 outlook of about 1-2% CER sales growth with adjusted EPS of at least $2.43 CER; the near-term catalyst is whether Q2 and later updates show this was a demand rebasing rather than a deeper slowdown in QuantiFERON and U.S. Life Sciences.

2026-12-31catalystGrowth-pillar launches need to rebuild 2026 credibility [#PR-2026-01-12]High impact

Management entered 2026 targeting commercialization, regulatory and automation milestones across Sample technologies, QIAstat-Dx, QIAcuity, QDI and QuantiFERON; after the Q1 outlook cut, successful launch execution and visible H2 recovery are the main path to restoring confidence in the 2028 pillar-growth framework.

2027-12-31catalystQuantiFERON automation and AI workflow expansion extend the TB franchise [#PR-2026-05-07]High impact

QIAGEN's May 7 company release outlined a late-2027 target for a fully automated QuantiFERON Sample-to-Insight workflow integrating Diasorin LIAISON systems with Inpeco automation and a separate AI-enabled TB progression risk tool; this supports the long-term TB franchise narrative, but it is too far out to offset the current 2026 immigration-testing demand reset by itself.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology